Cas:330194-05-3 6-bromo-2-(4-methylphenyl)quinoline-4-carboxylic acid manufacturer & supplier

Chemical Name:6-bromo-2-(4-methylphenyl)quinoline-4-carboxylic acid

CAS.NO:330194-05-3

Synonyms:6-bromo-2-p-tolylquinoline-4-carboxylic acid

Molecular Formula:C₁₇H₁₂BrNO₂

Molecular Weight:342.18700

HS Code:2933499090

Physical and Chemical Properties:

Melting point:N/A

Boiling point:N/A

Density:N/A

Index of Refraction:

PSA:50.19000

Exact Mass:341.00500

LogP:4.67090

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:

Packing Group:

Contact us for information like 6-bromo-2-p-tolylquinoline-4-carboxylic acid chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,6-bromo-2-p-tolylquinoline-4-carboxylic acid physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,6-bromo-2-p-tolylquinoline-4-carboxylic acid Use and application,6-bromo-2-p-tolylquinoline-4-carboxylic acid technical grade,usp/ep/jp grade.

Related News: From the perspective of product structure, the varieties of these enterprises are mainly concentrated in vitamins, antipyretics and analgesics, antibiotics and corticosteroids (ie bulk drug substances). 6-bromo-2-(4-methylphenyl)quinoline-4-carboxylic acid manufacturer In April 2019, Glenmark had received approval from the Drugs Controller General of India (DCGI) for Remogliflozin Etabonate after successfully completing Phase-3 clinical trials. 6-bromo-2-(4-methylphenyl)quinoline-4-carboxylic acid supplier From the perspective of product structure, the varieties of these enterprises are mainly concentrated in vitamins, antipyretics and analgesics, antibiotics and corticosteroids (ie bulk drug substances). 6-bromo-2-(4-methylphenyl)quinoline-4-carboxylic acid vendor Characteristic APIs are usually more complex in structure, and their synthesis involves a variety of technologies such as chiral synthesis, green synthesis, and catalysis, which requires high research and development capabilities in the production process of API companies. 6-bromo-2-(4-methylphenyl)quinoline-4-carboxylic acid factory The GLOW trial doesn’t yet have the answer to that question, but Tendler pointed to encouraging early evidence from the regimen’s phase 2 trial, dubbed CAPTIVATE. Among eight patients who progressed after stopping the fixed-duration combo, six responded to subsequent Imbruvica monotherapy, while the other two didn’t have a response report, according to data presented at the recent American Society of Clinical Oncology annual meeting.